Lavipharm S.A. (ATH:LAVI)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Production and Distribution of Pharmaceutical Products	62.58M	52.95M	-	-	-
Medicines	-	-	47.44M	34.18M	34.28M
Services	-	-	400.00K	1.45M	1.43M
Parapharmaceuticals	-	-	-	3.43M	4.02M
Total	62.58M	52.95M	47.84M	39.06M	39.72M

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Greece	38.81M	28.44M	21.55M	31.18M	27.58M
European Union	17.62M	18.83M	22.75M	12.20M	10.41M
Other countries	6.15M	5.68M	3.55M	2.62M	1.73M
Total	62.58M	52.95M	47.84M	46.01M	39.72M

Data Source: S&P Global Market Intelligence Last updated: Sep 17, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 13, 2026

Data Sources Report a data error